Apellis Pharmaceuticals, Inc. (APLS)

In October 2025, Apellis reported strong third-quarter financial results. In December 2025, Weiss Ratings restated a "sell (d)" rating on Apellis Pharmaceuticals' shares. In January 2026, Apellis announced preliminary full-year 2025 U.S. net product revenues, leading to a decline in the company's share price. In February 2026, Apellis reported its fourth-quarter and full-year 2025 financial results, and Mikael Dolsten, M.D., Ph.D., joined the Board of Directors. In March 2026, Biogen Inc. announced its definitive agreement to acquire Apellis Pharmaceuticals for $41.00 per share in cash, causing Apellis shares to more than double. In April 2026, Apellis Pharmaceuticals reached a new 52-week high, and several analysts adjusted their price targets and ratings.

Demand for SYFOVRE may experience fluctuations tied to the end of the year. EMPAVELI indicates a generally consistent demand driven by unmet medical needs in rare diseases. External factors related to patient access and financial support can influence demand and sales, potentially introducing a form of seasonality or variability not directly tied to disease prevalence.

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutic compounds for diseases with high unmet needs. The company operates in the Healthcare sector, specifically in the Biotechnology and Pharmaceuticals & Biotech industries, and focuses on inhibiting the complement system at the C3 level. Apellis has two FDA-approved, C3-targeting medicines: SYFOVRE for geographic atrophy (GA) secondary to age-related macular degeneration and EMPAVELI for paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy (C3G), and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The company's pipeline includes further development of EMPAVELI for indications such as focal segmental glomerulosclerosis (FSGS) and delayed graft function (DGF), as well as APL-3007 and APL-9099, among other preclinical programs. Apellis has collaboration and license agreements with Swedish Orphan Biovitrum AB (publ) for pegcetacoplan and with Beam Therapeutics, Inc. for gene-editing technology.

Apellis Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts, United States. The company has a global presence with subsidiaries and offices in several countries, including Australia, Austria, Bermuda, Canada, Cayman Islands, France, Germany, Ireland, Italy, Netherlands, Sweden, Switzerland, and the United Kingdom.

Apellis Pharmaceuticals' brand reputation has been influenced by positive product developments and some challenges. The company has been recognized for developing the first-ever therapy for geographic atrophy (SYFOVRE) and the first treatment for C3G and primary IC-MPGN (EMPAVELI). However, SYFOVRE faced safety setbacks and a refusal to approve the drug in the EU, impacting its perceived potential. EMPAVELI's strong launch and market penetration in rare kidney diseases have been highlighted, suggesting a positive impact on the company's reputation. The recent acquisition by Biogen could also be seen as a validation of Apellis' assets and scientific advancements.

Apellis Pharmaceuticals' ownership is primarily concentrated among institutional investors, who collectively hold a significant majority of the company's stock. Major institutional shareholders include Wellington Management Group Llp, Avoro Capital Advisors LLC, Vanguard Group Inc, Morgan Stanley, Deep Track Capital, LP, RTW Investments, Lp, BlackRock, Inc., State Street Corp, UBS Group AG, and Suvretta Capital Management, Llc. Individual insiders also maintain stakes in the company, representing 3.98% of the company's shares as of May 2025.